Synta Pharmaceuticals (SNTA) 3.97 $SNTA
5 Stocks Insiders Love Right Now
at The Street - Wed Apr 16, 12:06PM CDT
Insiders at these companies are scooping up shares of their own stock lately.
Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner
Business Wire - Mon Apr 14, 7:02AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the entry into a Subscription Agreement with an entity affiliated with Bruce Kovner, one of Synta's directors and its largest stockholder, to sell 1,250,000 shares of its common stock at a price of $4.01 per share. The proceeds to Synta are expected to be approximately $5.0 million after deducting estimated offering expenses payable by Synta. The shares were offered directly without a placement agent, underwriter, broker or dealer.
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research
Business Wire - Mon Apr 07, 6:30AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company's Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Poster presentations include:
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Jumps 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:44AM CDT
Synta Pharmaceuticals Corp. was a big mover last session, as the company saw its shares rise 9.5% on the day.
Why Synta Pharmaceuticals, Herman Miller, and Tower Semiconductor Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Mar 20, 7:00PM CDT
After yesterday's surprise comments from Fed Chair Janet Yellen regarding the potential for interest rate hikes by next year, many investors weren't sure how stocks would react the morning after. But encouraging economic news from a rise in the...
Guess and Lennar are big market movers
AP - Thu Mar 20, 4:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Synta Pharmaceuticals Corp. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 1:33PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals , a clinical-stage...
Morning Movers in Biotech: Agenus Inc., GlaxoSmithKline plc and Synta Pharmaceuticals Corp.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:17AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 9th European Breast Cancer Conference
Business Wire - Thu Mar 20, 4:45AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the Company's lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The results are being presented today in an oral session at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland at 9:45 AM local time.
Coverage of Top Gainers -- Research on Synta Pharma, BG Medicine, Abraxas Petroleum, and xG Technology
PR Newswire - Wed Mar 19, 7:25AM CDT
The US markets saw a positive sentiment on Tuesday, March 18, 2014, with the NASDAQ Composite closing at 4,333.31, up 1.25%, the Dow Jones Industrial Average ending the session at 16,336.19, up 0.55% and the S&P 500 edging 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Synta Pharmaceuticals Corp. (NASDAQ: SNTA), BG Medicine Inc. (NASDAQ: BGMD), Abraxas Petroleum Corp. (NASDAQ: AXAS), and xG Technology Inc. (NASDAQ: XGTI). Free technical research on SNTA, BGMD, AXAS and XGTI can be downloaded upon signing up at:
Why Synta Pharmaceuticals Corp. Plunged Today
Brian Pacampara, The Motley Fool - Motley Fool - Wed Mar 12, 10:46AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals sank 16% today...
Stock to Watch: Synta Pharmaceuticals Down 16.5% (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 10:13AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) is one of today's worst performing low-priced stocks, down 16.5% to $4.41 on 1.3x average daily volume. Thus far today, Synta Pharmaceuticals has traded 3.3 million shares, vs. average volume of 2.6 million shares per day. The stock has underperformed the Dow (-16.5% to the Dow's -0.2%) and underperformed the S&P 500 (-16.5% to the S&P's -0.2%) during today's trading.
Geron, Zogenix, Synta Pharmaceuticals, and Pfizer: Today’s Top Health Care Stories
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 12, 8:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Geron , ...
Downgrade Alert for Synta Pharmaceuticals (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 7:04AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) was downgraded from Market Perform to Underperform at BMO Capital today. The stock closed yesterday at $5.28 on volume of 5.4 million shares, above average daily volume of 2.6 million. Over the past year, Synta Pharmaceuticals has traded in a range of $3.70 to $10.74 and closed yesterday at $5.28, 43% above that low. Over the past week, the 200-day moving average (MA) has gone down 0.6% while the 50-day MA has advanced 0.2%.
Why Synta Pharmaceuticals Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals , a clinical-stage...
Today’s Top Biotech Stories: Myriad Genetics, Bayer, Amgen, and Synta
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 11, 9:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Myriad Genetics...
5 Stocks Insiders Love Right Now
at The Street - Wed Apr 16, 12:06PM CDT
Insiders at these companies are scooping up shares of their own stock lately.
Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner
Business Wire - Mon Apr 14, 7:02AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the entry into a Subscription Agreement with an entity affiliated with Bruce Kovner, one of Synta's directors and its largest stockholder, to sell 1,250,000 shares of its common stock at a price of $4.01 per share. The proceeds to Synta are expected to be approximately $5.0 million after deducting estimated offering expenses payable by Synta. The shares were offered directly without a placement agent, underwriter, broker or dealer.
Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Synta Announces Presentations at the 2014 Annual Meeting of the American Association of Cancer Research
Business Wire - Mon Apr 07, 6:30AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a selective Hsp90 inhibitor in clinical development by the company, and the company's Hsp90 inhibitor drug conjugates (HDC) will be presented at the 2014 Annual Meeting of the American Association of Cancer Research in San Diego, California. Poster presentations include:
Candidate Selection for Clinical Trials, Financial Results, and Patient Enrollments for Phase I Study - Analyst Notes on Synta, Ziopharm, Aastrom, Agios, and OncoMed
PR Newswire - Tue Mar 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Synta Pharmaceuticals Corp. (NASDAQ: SNTA), ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), Aastrom Biosciences, Inc. (NASDAQ: ASTM), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Synta Pharmaceuticals Corp. (SNTA) Catches Eye: Stock Jumps 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:44AM CDT
Synta Pharmaceuticals Corp. was a big mover last session, as the company saw its shares rise 9.5% on the day.
Why Synta Pharmaceuticals, Herman Miller, and Tower Semiconductor Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Mar 20, 7:00PM CDT
After yesterday's surprise comments from Fed Chair Janet Yellen regarding the potential for interest rate hikes by next year, many investors weren't sure how stocks would react the morning after. But encouraging economic news from a rise in the...
Guess and Lennar are big market movers
AP - Thu Mar 20, 4:29PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Synta Pharmaceuticals Corp. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 1:33PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals , a clinical-stage...
Morning Movers in Biotech: Agenus Inc., GlaxoSmithKline plc and Synta Pharmaceuticals Corp.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:17AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 9th European Breast Cancer Conference
Business Wire - Thu Mar 20, 4:45AM CDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the Company's lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. The results are being presented today in an oral session at the 9th European Breast Cancer Conference (EBCC) in Glasgow, Scotland at 9:45 AM local time.
Coverage of Top Gainers -- Research on Synta Pharma, BG Medicine, Abraxas Petroleum, and xG Technology
PR Newswire - Wed Mar 19, 7:25AM CDT
The US markets saw a positive sentiment on Tuesday, March 18, 2014, with the NASDAQ Composite closing at 4,333.31, up 1.25%, the Dow Jones Industrial Average ending the session at 16,336.19, up 0.55% and the S&P 500 edging 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Synta Pharmaceuticals Corp. (NASDAQ: SNTA), BG Medicine Inc. (NASDAQ: BGMD), Abraxas Petroleum Corp. (NASDAQ: AXAS), and xG Technology Inc. (NASDAQ: XGTI). Free technical research on SNTA, BGMD, AXAS and XGTI can be downloaded upon signing up at:
Why Synta Pharmaceuticals Corp. Plunged Today
Brian Pacampara, The Motley Fool - Motley Fool - Wed Mar 12, 10:46AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals sank 16% today...
Stock to Watch: Synta Pharmaceuticals Down 16.5% (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 10:13AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) is one of today's worst performing low-priced stocks, down 16.5% to $4.41 on 1.3x average daily volume. Thus far today, Synta Pharmaceuticals has traded 3.3 million shares, vs. average volume of 2.6 million shares per day. The stock has underperformed the Dow (-16.5% to the Dow's -0.2%) and underperformed the S&P 500 (-16.5% to the S&P's -0.2%) during today's trading.
Geron, Zogenix, Synta Pharmaceuticals, and Pfizer: Today’s Top Health Care Stories
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 12, 8:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Geron , ...
Downgrade Alert for Synta Pharmaceuticals (SNTA)
Comtex SmarTrend(R) - Wed Mar 12, 7:04AM CDT
Synta Pharmaceuticals (NASDAQ:SNTA) was downgraded from Market Perform to Underperform at BMO Capital today. The stock closed yesterday at $5.28 on volume of 5.4 million shares, above average daily volume of 2.6 million. Over the past year, Synta Pharmaceuticals has traded in a range of $3.70 to $10.74 and closed yesterday at $5.28, 43% above that low. Over the past week, the 200-day moving average (MA) has gone down 0.6% while the 50-day MA has advanced 0.2%.
Why Synta Pharmaceuticals Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 1:55PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Synta Pharmaceuticals , a clinical-stage...
Today’s Top Biotech Stories: Myriad Genetics, Bayer, Amgen, and Synta
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 11, 9:27AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Myriad Genetics...
